Axon Enterprise, Inc $AXON Stock Bought by Diversified Trust Co

Diversified Trust Co increased its position in Axon Enterprise, Inc (NASDAQ:AXON) by 470.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 79,246 shares of the biotechnology company’s stock after purchasing an additional 65,351 shares during the quarter. Axon Enterprise makes up 0.7% of Diversified Trust Co’s holdings, making the stock its 20th largest position. Diversified Trust Co’s holdings in Axon Enterprise were worth $33,483,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the company. Aberdeen Group plc increased its position in Axon Enterprise by 429.4% during the third quarter. Aberdeen Group plc now owns 281,029 shares of the biotechnology company’s stock worth $122,674,000 after buying an additional 227,949 shares during the last quarter. William Blair Investment Management LLC bought a new stake in Axon Enterprise in the third quarter valued at approximately $2,729,000. Allworth Financial LP raised its stake in Axon Enterprise by 8,015.9% in the third quarter. Allworth Financial LP now owns 504,079 shares of the biotechnology company’s stock valued at $212,983,000 after buying an additional 497,868 shares during the period. Private Advisory Group LLC bought a new stake in Axon Enterprise in the third quarter valued at approximately $6,940,000. Finally, Eurizon Capital SGR S.p.A. lifted its position in shares of Axon Enterprise by 6,058.4% in the third quarter. Eurizon Capital SGR S.p.A. now owns 1,593,304 shares of the biotechnology company’s stock valued at $673,203,000 after buying an additional 1,567,432 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $315.43 on Friday. The company has a market capitalization of $25.69 billion, a price-to-earnings ratio of 101.10, a PEG ratio of 5.84 and a beta of 1.48. The company has a current ratio of 3.00, a quick ratio of 2.60 and a debt-to-equity ratio of 0.76. Axon Enterprise, Inc has a 12 month low of $291.45 and a 12 month high of $665.07. The stock’s 50 day moving average is $417.79 and its 200-day moving average is $467.68.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.89 by ($0.17). The firm had revenue of $908.55 million for the quarter, compared to analyst estimates of $934.33 million. Axon Enterprise had a return on equity of 3.87% and a net margin of 7.56%. The business’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.17 earnings per share. Equities research analysts expect that Axon Enterprise, Inc will post 2.10 EPS for the current year.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, insider Isaiah Fields sold 1,017 shares of the company’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $480.45, for a total value of $488,617.65. Following the transaction, the insider directly owned 56,264 shares of the company’s stock, valued at $27,032,038.80. This represents a 1.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick Smith sold 10,000 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $508.99, for a total value of $5,089,900.00. Following the transaction, the chief executive officer owned 3,118,012 shares in the company, valued at $1,587,036,927.88. The trade was a 0.32% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 37,397 shares of company stock valued at $21,234,034. Corporate insiders own 4.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Craig Hallum downgraded Axon Enterprise from a “buy” rating to a “hold” rating and set a $390.00 target price for the company. in a research note on Friday, November 6th. JPMorgan Chase & Co. decreased their target price on Axon Enterprise from $755.00 to $610.00 and set an “overweight” rating on the stock in a report on Friday, November 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Tuesday, November 3rd. Northcoast Research increased their price target on Axon Enterprise from $650.00 to $680.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Morgan Stanley raised their price target on Axon Enterprise from $600.00 to $640.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and a consensus price target of $612.18.

About Axon Enterprise

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals. The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.